Any current/future capex/capital investment/strategic investment?

Capex for the next 2-3 years is expected to be around INR 50 crores to INR 100 crores, depending on the requirement. (Page 16) Earlier planned capex in the US is now partly substituted due to the acquisition of Apnar Pharmaceuticals, providing extended capacity. (Page 15-16) Expansion of the Atlanta Oral Solid Facility from 1 billion to 2 billion tablets is targeted to be completed by next year. (Page 15) Apnar acquisition adds manufacturing capacity in India, enabling shift of some low-margin products from the US to India, optimizing facility utilization and margin profiles. (Page 15) Aro

Future growth expectations in sales/revenue/volumes?

Senores Pharmaceuticals targets robust growth in FY’27 and beyond, building on 50% growth guidance for FY’26. The company expects to leverage Apnar acquisition and product launches (28 approved, 22 in development) to drive growth over the next 6-8 quarters. Regulated market revenue mix is expected to shift towards 65% own products by FY’27, improving realizations and margins. Emerging market business to continue growing with 56 product commercializations underway, driving revenue from distributor-led and export models. Branded generics in India forecasted to grow significantly, with projected

Future growth expectations in earnings/operating earnings/profits/EPS?

The company has recorded 100% PAT growth for two consecutive years but considers repeating this level in FY’27 as "a little asking too much" due to the higher base (INR650+ crores PAT expected this year). Targets a very decent top-line growth and slightly better bottom-line growth in FY’27. EBITDA margins in the US regulated market expected to sustainably remain around 40%, with possible 1% improvement as more own products get commercialized. Emerging markets EBITDA margins anticipated to improve to 18-22% in FY’27 and continue gaining modestly thereafter. Apnar acquisition expected to contrib

Current/ Expected Orderbook/ Pending Orders?

The transcript on page 17 does not explicitly mention the current or expected order book or pending orders in numeric terms. Swapnil Shah mentions that the company will keep updating the investor community on development sets and orders regularly. The company is closely monitoring facility utilization and transitions of products from the US to India to optimize margins and capacity. They have a strong product pipeline with 28 approved ANDAs yet to be launched over the next 6 to 8 quarters and 22 under development. The acquisition of Apnar has added manufacturing capacity and product portfolios

IN US

Sale is live|00:00:00left today

Senores Pharmaceuticals LtdQ4 FY27Pharmaceuticals & Biotechnology

Senores Pharmaceuticals Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,270P/E: 41.9Market Cap: ₹4.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Senores Pharmaceuticals targets robust growth in FY’27 and beyond, building on 50% growth guidance for FY’26.
→The company expects to leverage Apnar acquisition and product launches (28 approved, 22 in development) to drive growth over the next 6-8 quarters.
→Regulated market revenue mix is expected to shift towards 65% own products by FY’27, improving realizations and margins.
→Emerging market business to continue growing with 56 product commercializations underway, driving revenue from distributor-led and export models.
→Branded generics in India forecasted to grow significantly, with projected revenues of INR40-50 crores in FY’26 and INR80+ crores next year.
→Overall, a 25%+ topline growth target is indicated, with potential for better bottom line growth, though 100% PAT growth is deemed unlikely.
→Capacity expansions in India and US (including transfer of low-margin products to India) will support volume and margin improvements.

Margin guidance

Category 3

→The company has recorded 100% PAT growth for two consecutive years but considers repeating this level in FY’27 as "a little asking too much" due to the higher base (INR650+ crores PAT expected this year).
→Targets a very decent top-line growth and slightly better bottom-line growth in FY’27.
→EBITDA margins in the US regulated market expected to sustainably remain around 40%, with possible 1% improvement as more own products get commercialized.
→Emerging markets EBITDA margins anticipated to improve to 18-22% in FY’27 and continue gaining modestly thereafter.
→Apnar acquisition expected to contribute INR120-150 crores revenue in FY’27, with margin expansion as utilization improves.
→Focus on cautious growth visibility quarter-over-quarter with multiple levers: product launches, capacity expansion, and transitioning production from US to India.
→Management refrains from giving concrete 100% growth guidance for FY’27 but optimistic about strong growth momentum and margin improvement.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

- Recently, promoters did a small pledge of shares mainly to consolidate some borrowings; no plans for increased pledging. - IPO proceeds include around INR100 crores earmarked for the Atlanta facility, which cannot be utilized for other purposes. - After the Apnar acquisition, cash reserves reduced, leaving about INR25 crores as of December 31, 2025. - Management anticipates needing an additional infusion of INR75 crores to INR100 crores over the next 12 months, primarily for new product acquisitions (ANDAs) and working capital. - To raise this amount, promoters have opted for a warrant structure allowing 25% contribution upfront, with the balance contributed over 6-12 months as needed. - The company did not find it efficient to tap the market for a small amount, hence the warrant-based fundraising. No mention of large-scale debt or equity fundraising currently planned beyond this.

Order book

Yes

→The transcript on page 17 does not explicitly mention the current or expected order book or pending orders in numeric terms.
→Swapnil Shah mentions that the company will keep updating the investor community on development sets and orders regularly.
→The company is closely monitoring facility utilization and transitions of products from the US to India to optimize margins and capacity.
→They have a strong product pipeline with 28 approved ANDAs yet to be launched over the next 6 to 8 quarters and 22 under development.
→The acquisition of Apnar has added manufacturing capacity and product portfolios, expanding the order book potential.
→Commercialization of 56 recently approved products in emerging markets is underway and expected to contribute substantially.
→Overall, there is a positive outlook on orders linked to product launches, acquisitions, and market expansion, but exact order book numbers are not disclosed.

Capex plans

Yes

→Capex for the next 2-3 years is expected to be around INR 50 crores to INR 100 crores, depending on the requirement. (Page 16)
→Earlier planned capex in the US is now partly substituted due to the acquisition of Apnar Pharmaceuticals, providing extended capacity. (Page 15-16)
→Expansion of the Atlanta Oral Solid Facility from 1 billion to 2 billion tablets is targeted to be completed by next year. (Page 15)
→Apnar acquisition adds manufacturing capacity in India, enabling shift of some low-margin products from the US to India, optimizing facility utilization and margin profiles. (Page 15)
→Around INR 100 crores from IPO proceeds is earmarked specifically for the Atlanta facility and cannot be used elsewhere. (Page 13)
→An additional funding infusion of INR 75-100 crores over the next 12 months may be needed for new product acquisitions and working capital, managed partly through promoter warrants. (Page 13)

How does Senores Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Senores Pharmaceuticals Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Senores Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio